599 related articles for article (PubMed ID: 32768247)
1. Comparative Effectiveness and Safety of Direct-acting Oral Anticoagulants and Warfarin in Patients with Venous Thromboembolism and Active Cancer: An Observational Analysis.
Dawwas GK; Dietrich E; Smith SM; Davis K; Park H
Clin Ther; 2020 Sep; 42(9):e161-e176. PubMed ID: 32768247
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
Coleman CI; Bunz TJ; Turpie AGG
Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
[TBL] [Abstract][Full Text] [Related]
3. Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism.
Zakai NA; Walker RF; MacLehose RF; Adam TJ; Alonso A; Lutsey PL
J Thromb Haemost; 2018 Dec; 16(12):2403-2412. PubMed ID: 30240508
[TBL] [Abstract][Full Text] [Related]
4. Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
Wu C; Alotaibi GS; Alsaleh K; Linkins LA; McMurtry MS
Thromb Res; 2015 Feb; 135(2):243-8. PubMed ID: 25488466
[TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes of Direct Oral Anticoagulants vs Warfarin for Extended Treatment of Venous Thromboembolism.
Fang MC; Reynolds K; Fan D; Prasad PA; Sung SH; Portugal C; Garcia E; Go AS
JAMA Netw Open; 2023 Aug; 6(8):e2328033. PubMed ID: 37581888
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data.
Costa OS; Beyer-Westendorf J; Ashton V; Milentijevic D; Moore KT; Bunz TJ; Coleman CI
J Thromb Thrombolysis; 2021 Feb; 51(2):349-358. PubMed ID: 32588288
[TBL] [Abstract][Full Text] [Related]
7. Trajectories of Oral Anticoagulation Adherence and Associated Clinical Outcomes During Long-Term Anticoagulation Among Medicare Beneficiaries With Venous Thromboembolism.
Park H; Jones BL; Huang PL; Kang HR; Dietrich EA; DeRemer CE; Lo-Ciganic WH
Ann Pharmacother; 2023 Dec; 57(12):1349-1360. PubMed ID: 36999519
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state.
Coleman CI; Turpie AGG; Bunz TJ; Baker WL; Beyer-Westendorf J
Thromb Res; 2018 Mar; 163():132-137. PubMed ID: 29407625
[TBL] [Abstract][Full Text] [Related]
9. Comparative Safety and Effectiveness of Direct Oral Anticoagulants and Warfarin during Chemotherapy in Cancer Patients with Venous Thromboembolism Aged 75 Years or Older: A Nationwide Inpatient Database Study.
Iwai C; Jo T; Konishi T; Kumazawa R; Matsui H; Fushimi K; Yasunaga H
Gerontology; 2023; 69(5):561-570. PubMed ID: 36502790
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism.
Dawwas GK; Smith SM; Dietrich E; Lo-Ciganic WH; Park H
Am J Health Syst Pharm; 2020 Jan; 77(3):188-195. PubMed ID: 31974557
[TBL] [Abstract][Full Text] [Related]
11. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis.
Cohen A; Keshishian A; Lee T; Wygant G; Rosenblatt L; Hlavacek P; Mardekian J; Wiederkehr D; Sah J; Luo X
Thromb Haemost; 2021 Mar; 121(3):383-395. PubMed ID: 33171521
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Direct Oral Anticoagulants vs Warfarin in Patients with Chronic Kidney Disease and Dialysis Patients: A Systematic Review and Meta-Analysis.
Chen HY; Ou SH; Huang CW; Lee PT; Chou KJ; Lin PC; Su YC
Clin Drug Investig; 2021 Apr; 41(4):341-351. PubMed ID: 33709339
[TBL] [Abstract][Full Text] [Related]
14. Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population.
Hlavacek P; Guo JD; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R
Curr Med Res Opin; 2019 Dec; 35(12):2043-2051. PubMed ID: 31387467
[No Abstract] [Full Text] [Related]
15. Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database.
Guo JD; Rajpura J; Hlavacek P; Keshishian A; Sah J; Delinger R; Mu Q; Mardekian J; Russ C; Okano GJ; Rosenblatt L
J Manag Care Spec Pharm; 2020 Aug; 26(8):1017-1026. PubMed ID: 32452277
[TBL] [Abstract][Full Text] [Related]
16. Survival outcomes with warfarin compared with direct oral anticoagulants in cancer-associated venous thromboembolism in the United States: A population-based cohort study.
Khan AM; Chiasakul T; Redd R; Patell R; McCarthy EP; Neuberg D; Zwicker JI
PLoS Med; 2022 May; 19(5):e1004012. PubMed ID: 35613184
[TBL] [Abstract][Full Text] [Related]
17. Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs.
Spyropoulos AC; Ashton V; Chen YW; Wu B; Peterson ED
Thromb Res; 2019 Oct; 182():159-166. PubMed ID: 31493618
[TBL] [Abstract][Full Text] [Related]
18. One-year adherence to warfarin treatment for venous thromboembolism in high-risk patients and its association with long-term risk of recurrent events.
Chen SY; Wu N; Gulseth M; LaMori J; Bookhart BK; Boulanger L; Fields L; Schein J
J Manag Care Pharm; 2013 May; 19(4):291-301. PubMed ID: 23627575
[TBL] [Abstract][Full Text] [Related]
19. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
Perales IJ; San Agustin K; DeAngelo J; Campbell AM
Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
[No Abstract] [Full Text] [Related]
20. Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism.
Kohn CG; Bunz TJ; Beyer-Westendorf J; Coleman CI
Eur J Haematol; 2019 Feb; 102(2):143-149. PubMed ID: 30328143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
